Wave Bioreactors Added to Macrogenics cGMP Manufacturing Facility
News Jan 12, 2006
The Wave Bioreactors® will enable MacroGenics - which is focused on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases - to produce monoclonal antibodies under current Good Manufacturing Practice standards.
"Wave Biotech's disposable cell culture technology is ideal for the MacroGenics application because it is scalable, up to 500 liters," said Vijay Singh, founder & president of Wave Biotech.
"Our large scale bioreactors use proprietary technology which has been tested and refined for the last 5 years, and we can also roll-in a large scale 500 liter production capability bioreactor into an existing facility today, without the requirements of piping or steam," added Singh, whom is the inventor of the Wave Bioreactor®.
Further he said, "There is no waiting period. All that is needed is to plug and play."
MacroGenics officially opened their new manufacturing facility on October 19th.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019